One reason seniors give their Medicare drug plan high marks is because they can choose among a wide range of drug plans. Nationwide, 1,169 Medicare Part D drug plans across 34 regions compete for seniors' patronage. The number of plans varies among states, from a low of 28 in Alaska, to a high of 39 Pennsylvania and West Virginia. But that's too many according to some within the Obama administration. Some Medicare administrators remain skeptical of the MMA — which was passed by the Bush administration with the help of congressional Democrats. The Bush administration wanted the Medicare drug program to be composed of private drug plans, whose primary mission is to vigorously compete for seniors' patronage. Since its inception, the MMA mandated a statutory, non-interference clause. Contract negotiations between drug makers, pharmacy networks and drug plan sponsors were strictly left to the respective parties. Drug plan sponsors were responsible for negotiating prices with drug companies and drug distributors, and contracting with pharmacy network providers to secure seniors the lowest possible drug prices.
That is, until now. In January 2014, CMS proposed new regulations that would restrict the ability of drug plans to offer seniors lower drug prices in return for patronizing a preferred network. Low prices are the result of bargaining power — the ability of the drug plan managers to steer business to drug providers that agree to low prices, and deny business to a firm if their bid isn't favorable.
The Obama administration wants to block drug plans from excluding the losing bidders — those drug provider networks that offered the highest prices during contract negotiations. The proposed regulatory change is not benign; it substantially weakens a drug plan's power to bargain for lower prices on behalf of seniors. Without the knowledge that a "losing bid" threatens drug plan managers with losing out on all potential business from enrollees in a given Medicare drug plan, pharmacy networks will have little reason to offer low prices. The incentive is for all competitors is to bid higher, knowing a losing bid does not mean losing business — but could mean charging higher prices.
Medicare Part D premiums have remained affordable since the MMA's inception because per capita drug spending has been far lower than projected. In 2013 the per capita cost was nearly 40 percent less than it was projected to be back in 2006.
According to the Federal Trade Commission, regulations that ban preferred networks raise prices and harm consumers. The actuarial firm Milliman estimates this regulatory change, proposed in January, would actually cost the Medicare program nearly $1 billion per year, and would add more than $9 billion to the cost of the Medicare Part D program over the next decade. Seniors seem to appreciate drug plans that feature low-priced, preferred pharmacy networks. Enrollment in this type of plan has shot up more than 60 percent in the past year. Seniors — and taxpayers — will be losers if this option is taken from them.
15 Excerpts That Show How Radical, Weird And Out of Touch College Campuses Have Become | John Hawkins